AACE convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications.
AACE/ACE Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis © 2016
Recent reports of diabetic ketoacidosis (DKA) occur-ring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among patients
Among the more than 20 million Americans whohave diabetes, approximately 30% of the cases are undi-agnosed (1).
Evidence-based medicine has generated many philosophical and pragmatic challenges to clinical care. Chief among these challenges is how to deliver culturally appropriate individualized endocrine care while adhering to evidence-based guidelines and algorithms developed for large heterogeneous populations.
Since its inception, the American Association of Clinical Endocrinologists (AACE) has advocated for the finest in endocrine education and state-of-the-art health-care delivery without regard to race, ethnicity, gender, age, country of origin, economic status, lifestyle, sexual orientation or domestic living arrangements.
A position statement by the American Association of Clinical Endocrinologists